65,600 Shares in Inogen, Inc $INGN Purchased by Strs Ohio

Strs Ohio bought a new stake in shares of Inogen, Inc (NASDAQ:INGN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 65,600 shares of the medical technology company's stock, valued at approximately $468,000. Strs Ohio owned 0.24% of Inogen at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC boosted its stake in shares of Inogen by 35.7% in the 1st quarter. Acadian Asset Management LLC now owns 1,028,322 shares of the medical technology company's stock valued at $7,325,000 after buying an additional 270,453 shares during the period. AQR Capital Management LLC boosted its stake in shares of Inogen by 30.1% in the 1st quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company's stock valued at $4,022,000 after buying an additional 130,381 shares during the period. DAFNA Capital Management LLC boosted its stake in shares of Inogen by 119.4% in the 1st quarter. DAFNA Capital Management LLC now owns 458,065 shares of the medical technology company's stock valued at $3,266,000 after buying an additional 249,275 shares during the period. Royce & Associates LP boosted its stake in shares of Inogen by 42.8% in the 1st quarter. Royce & Associates LP now owns 444,457 shares of the medical technology company's stock valued at $3,169,000 after buying an additional 133,258 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Inogen by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company's stock valued at $2,026,000 after buying an additional 41,002 shares during the period. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Stock Performance

NASDAQ:INGN opened at $8.66 on Tuesday. The firm has a market cap of $234.17 million, a P/E ratio of -8.17 and a beta of 1.78. The stock's 50 day simple moving average is $7.44 and its 200-day simple moving average is $7.08. Inogen, Inc has a 12-month low of $5.70 and a 12-month high of $12.91.

Inogen (NASDAQ:INGN - Get Free Report) last released its earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The business had revenue of $92.28 million for the quarter, compared to analyst estimates of $90.40 million. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts forecast that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, B. Riley started coverage on Inogen in a research note on Monday, June 16th. They issued a "buy" rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.